Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. (Q53341753)

13 May 2018

title

Kinetics of human acetylcholinesterase inhibition by the novel experimental Alzheimer therapeutic agent, tolserine. (English)

1 reference

13 May 2018

author

Mohammad Amjad Kamal

1

1 reference

13 May 2018

author name string

Greig NH

2

1 reference

13 May 2018

Alhomida AS

3

1 reference

13 May 2018

Al-Jafari AA

4

1 reference

13 May 2018

language of work or name

English

0 references

publication date

1 August 2000

1 reference

13 May 2018

published in

Biochemical Pharmacology

1 reference

13 May 2018

volume

60

1 reference

13 May 2018

issue

4

1 reference

13 May 2018

page(s)

561-570

1 reference

13 May 2018

The cholinergic system in Alzheimer's disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Potential role of muscarinic agonists in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Tacrine. A cause of fatal hepatotoxicity?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Donepezil use in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

The secretion of amyloid beta-peptides is inhibited in the tacrine-treated human neuroblastoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Effects of cholinesterase inhibitors on the secretion of beta-amyloid precursor protein in cell cultures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Kinetics of human erythrocyte acetylcholinesterase inhibition by a novel derivative of physostigmine: phenserine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Phenserine, a novel acetylcholinesterase inhibitor, attenuates impaired learning of rats in a 14-unit T-maze induced by blockade of the N-methyl-D-aspartate receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Alzheimer's disease: a central role for amyloid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Pharmacological modulation of Alzheimer's beta-amyloid precursor protein levels in the CSF of rats with forebrain cholinergic system lesions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Phenserine and ring C hetero-analogues: drug candidates for the treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

A new and rapid colorimetric determination of acetylcholinesterase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Kinetics of the inhibition of acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom by local anesthetics: procaine and tetracaine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

From molecular structure to Alzheimer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Acetylcholinesterase inhibition and anti-soman efficacy of homologs of physostigmine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Purification and characterization of acetylcholinesterase from desert cobra (Walterinnesia aegyptia) venom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Purifcation and properties of multiple forms of brain acetylcholinesterase (EC 3.1.1.7)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

The nature of the inhibition of camel retina acetylcholinesterase (EC 3.1.1.7) activity by tetrahydroaminoacridine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

General occurrence of binding to acetylcholinesterase-substrate complex in noncompetitive inhibition and in inhibition by substrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Changes in brain cholinesterases in senile dementia of Alzheimer type.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Acetylcholinesterase from human erythrocytes membranes: dimers as functional units

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Acetylcholinesterase: C-terminal domains, molecular forms and functional localization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Noncompetitive inhibition of acetylcholinesterase by eserine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2800%2900330-0

10.1016/S0006-2952(00)00330-0

7 January 2021

Identifiers

DOI

1 reference

13 May 2018

PubMed ID

10874131

1 reference

13 May 2018